Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1993 April; 91(4): 1269–1281.
PMCID: PMC288095

Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.


The human heart is a target organ for the octapeptide hormone, angiotensin II (Ang II). Recent studies suggest that the human heart contains a dual pathway of Ang II formation in which the major Ang II-forming enzymes are angiotensin I-converting enzyme (ACE) and chymase. Human heart chymase has recently been purified and its cDNA and gene cloned. This cardiac serine proteinase is the most efficient and specific Ang II-forming enzyme described. To obtain insights into the cardiac sites of chymase-dependent Ang II formation, we examined the cellular localization and regional distribution of chymase in the human heart. Electron microscope immunocytochemistry using an anti-human chymase antibody showed the presence of chymase-like immunoreactivity in the cardiac interstitium and in cytosolic granules of mast cells, endothelial cells, and some mesenchymal interstitial cells. In the cardiac interstitium, chymase-like immunoreactivity is associated with the extracellular matrix. In situ hybridization studies further indicated that chymase mRNA is expressed in endothelial cells and in interstitial cells, including mast cells. Tissue chymase levels were determined by activity assays and by Western blot analyses. Chymase levels were approximately twofold higher in ventricles than in atria. There were no significant differences in chymase levels in ventricular tissues obtained from non-failing donor hearts, failing ischemic hearts, or hearts from patients with ischemic cardiomyopathy. These findings suggest that a major site of chymase-dependent Ang II formation in the heart is the interstitium and that cardiac mast cells, mesenchymal interstitial cells, and endothelial cells are the cellular sites of synthesis and storage of chymase. In the human heart, because ACE levels are highest in the atria and chymase levels are highest in ventricles, it is likely that the relative contribution of ACE and chymase to cardiac Ang II formation varies with the cardiac chamber. Such differences may lead to differential suppression of cardiac Ang II levels during chronic ACE inhibitor therapy in patients with congestive heart failure.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (5.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev. 1977 Apr;57(2):313–370. [PubMed]
  • Waeber B, Gavras I, Brunner HR, Cook CA, Charocopos F, Gavras HP. Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity. Am Heart J. 1982 Mar;103(3):384–390. [PubMed]
  • Turini GA, Brunner HR, Gribic M, Waeber B, Gavras H. Improvement of chronic congestive heart-failure by oral captopril. Lancet. 1979 Jun 9;1(8128):1213–1215. [PubMed]
  • Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 Jun 12;314(24):1547–1552. [PubMed]
  • Fouad FM, El-Tobgi S, Tarazi RC, Bravo EL, Hart NJ, Shirey EK, Lim J. Captopril in congestive heart failure resistant to other vasodilators. Eur Heart J. 1984 Jan;5(1):47–54. [PubMed]
  • Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991 Aug;69(2):475–482. [PubMed]
  • Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res. 1991 Apr;68(4):905–921. [PubMed]
  • Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II receptors in normal and failing human hearts. J Clin Endocrinol Metab. 1989 Jul;69(1):54–66. [PubMed]
  • Moravec CS, Schluchter MD, Paranandi L, Czerska B, Stewart RW, Rosenkranz E, Bond M. Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation. 1990 Dec;82(6):1973–1984. [PubMed]
  • Chen SA, Chang MS, Chiang BN, Cheng KK, Lin CI. Electromechanical effects of angiotensin in human atrial tissues. J Mol Cell Cardiol. 1991 Apr;23(4):483–493. [PubMed]
  • Aceto JF, Baker KM. [Sar1]angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol. 1990 Mar;258(3 Pt 2):H806–H813. [PubMed]
  • Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990 Apr;66(4):883–890. [PubMed]
  • Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990 Dec 25;265(36):22348–22357. [PubMed]
  • Urata H, Kinoshita A, Perez DM, Misono KS, Bumpus FM, Graham RM, Husain A. Cloning of the gene and cDNA for human heart chymase. J Biol Chem. 1991 Sep 15;266(26):17173–17179. [PubMed]
  • Kinoshita A, Urata H, Bumpus FM, Husain A. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart. J Biol Chem. 1991 Oct 15;266(29):19192–19197. [PubMed]
  • Wolosewick JJ, De Mey J, Meininger V. Ultrastructural localization of tubulin and actin in polyethylene glycol-embedded rat seminiferous epithelium by immunogold staining. Biol Cell. 1983;49(3):219–226. [PubMed]
  • Boehm KD, Kelley MF, Ilan J, Ilan J. The interleukin 2 gene is expressed in the syncytiotrophoblast of the human placenta. Proc Natl Acad Sci U S A. 1989 Jan;86(2):656–660. [PubMed]
  • Craig SS, Schwartz LB. Tryptase and chymase, markers of distinct types of human mast cells. Immunol Res. 1989;8(2):130–148. [PubMed]
  • Craig SS, Schechter NM, Schwartz LB. Ultrastructural analysis of maturing human T and TC mast cells in situ. Lab Invest. 1989 Jan;60(1):147–157. [PubMed]
  • Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol. 1982 Oct;95(1):355–360. [PMC free article] [PubMed]
  • Caughey GH, Zerweck EH, Vanderslice P. Structure, chromosomal assignment, and deduced amino acid sequence of a human gene for mast cell chymase. J Biol Chem. 1991 Jul 15;266(20):12956–12963. [PubMed]
  • Benfey PN, Yin FH, Leder P. Cloning of the mast cell protease, RMCP II. Evidence for cell-specific expression and a multi-gene family. J Biol Chem. 1987 Apr 15;262(11):5377–5384. [PubMed]
  • Serafin WE, Reynolds DS, Rogelj S, Lane WS, Conder GA, Johnson SS, Austen KF, Stevens RL. Identification and molecular cloning of a novel mouse mucosal mast cell serine protease. J Biol Chem. 1990 Jan 5;265(1):423–429. [PubMed]
  • Serafin WE, Sullivan TP, Conder GA, Ebrahimi A, Marcham P, Johnson SS, Austen KF, Reynolds DS. Cloning of the cDNA and gene for mouse mast cell protease 4. Demonstration of its late transcription in mast cell subclasses and analysis of its homology to subclass-specific neutral proteases of the mouse and rat. J Biol Chem. 1991 Jan 25;266(3):1934–1941. [PubMed]
  • Lagunoff D, Pritzl P. Characterization of rat mast cell granule proteins. Arch Biochem Biophys. 1976 Apr;173(2):554–563. [PubMed]
  • Woodbury RG, Everitt MT, Neurath H. Mast cell proteases. Methods Enzymol. 1981;80(Pt 100):588–609. [PubMed]
  • Caulfield JP, el-Lati S, Thomas G, Church MK. Dissociated human foreskin mast cells degranulate in response to anti-IgE and substance P. Lab Invest. 1990 Oct;63(4):502–510. [PubMed]
  • Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217–246. [PubMed]
  • Sayama S, Iozzo RV, Lazarus GS, Schechter NM. Human skin chymotrypsin-like proteinase chymase. Subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans. J Biol Chem. 1987 May 15;262(14):6808–6815. [PubMed]
  • Avraham S, Stevens RL, Nicodemus CF, Gartner MC, Austen KF, Weis JH. Molecular cloning of a cDNA that encodes the peptide core of a mouse mast cell secretory granule proteoglycan and comparison with the analogous rat and human cDNA. Proc Natl Acad Sci U S A. 1989 May;86(10):3763–3767. [PubMed]
  • Jenne DE, Tschopp J. Angiotensin II-forming heart chymase is a mast-cell-specific enzyme. Biochem J. 1991 Jun 1;276(Pt 2):567–568. [PubMed]
  • Kaminer MS, Lavker RM, Walsh LJ, Whitaker D, Zweiman B, Murphy GF. Extracellular localization of human connective tissue mast cell granule contents. J Invest Dermatol. 1991 Jun;96(6):857–863. [PubMed]
  • Remington SJ, Woodbury RG, Reynolds RA, Matthews BW, Neurath H. The structure of rat mast cell protease II at 1.9-A resolution. Biochemistry. 1988 Oct 18;27(21):8097–8105. [PubMed]
  • Schwartz LB, Lewis RA, Austen KF. Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem. 1981 Nov 25;256(22):11939–11943. [PubMed]
  • Goldstein SM, Kaempfer CE, Proud D, Schwartz LB, Irani AM, Wintroub BU. Detection and partial characterization of a human mast cell carboxypeptidase. J Immunol. 1987 Oct 15;139(8):2724–2729. [PubMed]
  • Salvesen G, Farley D, Shuman J, Przybyla A, Reilly C, Travis J. Molecular cloning of human cathepsin G: structural similarity to mast cell and cytotoxic T lymphocyte proteinases. Biochemistry. 1987 Apr 21;26(8):2289–2293. [PubMed]
  • Frommherz KJ, Faller B, Bieth JG. Heparin strongly decreases the rate of inhibition of neutrophil elastase by alpha 1-proteinase inhibitor. J Biol Chem. 1991 Aug 15;266(23):15356–15362. [PubMed]
  • Nussberger J, Brunner DB, Waeber B, Brunner HR. Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension. 1986 Jun;8(6):476–482. [PubMed]
  • Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens. 1984 Jun;2(3):277–284. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation